News Conference News AHA 2025 Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials Yael L. Maxwell November 13, 2025
Presentation AHA 2024 Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement Presenter: Chisato Izumi November 17, 2024
News Conference News AHA 2024 ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery Yael L. Maxwell November 17, 2024
News Conference News AHA 2024 Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients Shelley Wood November 16, 2024
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2020 High Burden of Post-CABG A-fib After Hospital Discharge: SEARCH-AF Michael O'Riordan November 16, 2020
News Conference News AHA 2019 Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial Shelley Wood November 18, 2019
News Conference News AHA 2018 Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF Todd Neale November 11, 2018
News Conference News AHA 2017 One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs Shelley Wood November 14, 2017
News Conference News AHA 2016 Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding Shelley Wood November 21, 2016
News Conference News AHA 2016 Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias Shelley Wood November 21, 2016